WASHINGTON — The Trump administration’s deal to expand access to and lower the cost of weight loss drugs has left industry leaders, public health experts, and patients with a host of open questions.
The administration’s agreements with Eli Lilly and Novo Nordisk center on their GLP-1 offerings, which officials said would now be available to more Americans — at prices that would ultimately save the government money.
But the details of the deal — including the policy underpinnings, economic implications, and public health outcomes — are likely to determine whether the bold claims from the president become a reality.
